# Steven P. Treon

Source: https://onco.cc/people/steven-treon/  
OnCo record `steven-treon` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Discovered the MYD88 mutation that defines Waldenström macroglobulinaemia and led the trial that made ibrutinib its first approved drug.

## Summary

Steven Treon led the whole-genome sequencing that found the MYD88 L265P mutation in more than 90% of Waldenström macroglobulinaemia, a diagnostic marker and therapeutic target, and then the pivotal trial of ibrutinib that produced the disease's first FDA approval. He identified CXCR4 mutations as a resistance mechanism and directs the world's largest Waldenström research centre at Dana-Farber.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; waldenstrom; genomics
- Role: Director, Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute
- Specialisms: Waldenström macroglobulinaemia; MYD88 and CXCR4 genomics; BTK inhibitors; Rare lymphomas

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Treon%20SP%5BAuthor%5D%20Waldenstrom

## Connected records

- cancers: [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)

---
JSON: https://onco.cc/api/v1/entities/steven-treon.json